TNFRSF6B and Sepsis: The aforementioned hypothesis plausibly elucidates the paradox that supplementation of DcR3 may serve as a promising immunotherapeutic agent for numerous inflammatory diseases including sepsis, while its endogenous counterpart functions as a biomarker indicative of organ dysfunction and dismal outcomes (Su et al., 2023).